Skip To Main Content
Barbara R. Hauser on Muck Rack

Barbara R. Hauser

As seen in: LinkedIn, Wealth Management, Portfolio Management Research, CampdenFB
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara R.

Contact Barbara R., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis (Front. Endocrinol., (2021), 12, 782118, 10.3389/fendo.2021.782118)

|
By Kaleen N. Hayes, Ulrike Baschant, Technische Universität Dresden, Barbara R. Hauser
| tu-dresden.de
In the article as published originally, Elizabeth M. Winter was erroneously presented as the corresponding author instead of Ulrike Baschant. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Open in Who Shared Issue with article?

Advising Private Clients Around the World

|
By Barbara R. Hauser
| Wealth Management Verified
https://www.wealthmanagement.com/sites/wealthmanagement.com/files/logos/Wealth-Management-Logo-white.png Skip navigation Resources Trusts & Estates Latest Issue Subscribe to Trusts & Estates Premium Content Trusts and Estates Digital Edition Archive I periodically compile an update of developments in jurisdictions around the world. In 2018, I focused on family offices.1 Now, I’ve added client private services to the mix.
Open in Who Shared View Duplicates (5) Issue with article?

When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

|
By Kaleen N. Hayes, Ulrike Baschant, Technische Universität Dresden, Barbara R. Hauser
| tu-dresden.de
Glucocorticoid-induced osteoporosis (GIOP) leads to fractures in up to 40% of patients with chronic glucocorticoid (GC) therapy when left untreated. GCs rapidly increase fracture risk, and thus many patients with anticipated chronic GC exposures should start anti-osteoporosis pharmacotherapy to prevent fractures.
Open in Who Shared Issue with article?
See all 11 licensed articles (13 Total)